Kompanija Dunav Osiguranje a.d.o. (BELEX:DNOS)
1,667.00
-13.00 (-0.77%)
At close: Aug 1, 2025
Regulus Therapeutics Balance Sheet
Financials in millions RSD. Fiscal year is January - December.
Millions RSD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Investments in Debt Securities | 59.75 | 59.79 | 59.98 | 110.2 | 110.52 | Upgrade |
Investments in Equity & Preferred Securities | 50.07 | 50.07 | 50.12 | 50.12 | 53.02 | Upgrade |
Other Investments | 46,688 | 40,171 | 35,707 | 36,875 | 34,912 | Upgrade |
Total Investments | 48,076 | 41,367 | 36,617 | 38,108 | 36,610 | Upgrade |
Cash & Equivalents | 3,383 | 3,544 | 2,492 | 2,202 | 3,171 | Upgrade |
Reinsurance Recoverable | 10,216 | 8,425 | 6,789 | 6,276 | 6,366 | Upgrade |
Other Receivables | 11,441 | 8,932 | 7,938 | 6,516 | 5,989 | Upgrade |
Deferred Policy Acquisition Cost | 4,075 | 3,847 | 3,509 | 3,585 | 2,880 | Upgrade |
Property, Plant & Equipment | 16,609 | 16,420 | 12,289 | 11,243 | 9,570 | Upgrade |
Other Intangible Assets | 224.65 | 148.36 | 79.07 | 98.35 | 45.26 | Upgrade |
Other Current Assets | 703.41 | 1,464 | 834.93 | 725.14 | 356.59 | Upgrade |
Other Long-Term Assets | 1,107 | 156.62 | 961.41 | 127.54 | 111.67 | Upgrade |
Total Assets | 95,835 | 84,304 | 71,510 | 68,881 | 65,100 | Upgrade |
Accounts Payable | 1,528 | 469.86 | 350.8 | 614.45 | 251.69 | Upgrade |
Accrued Expenses | 943.88 | 1,158 | 964.42 | 842.66 | 604.69 | Upgrade |
Insurance & Annuity Liabilities | 8,066 | 7,700 | 1,890 | 7,282 | 6,697 | Upgrade |
Unpaid Claims | 26,618 | 23,014 | 19,824 | 18,057 | 17,795 | Upgrade |
Unearned Premiums | 22,199 | 19,379 | 16,838 | 15,298 | 14,552 | Upgrade |
Reinsurance Payable | 1,533 | 1,591 | 1,855 | 1,606 | 1,223 | Upgrade |
Current Income Taxes Payable | 320.45 | 182.37 | 46.66 | 369.58 | 441.95 | Upgrade |
Long-Term Debt | 926.42 | 1,105 | 758.16 | 76.75 | 13.66 | Upgrade |
Long-Term Leases | 422.76 | 557.1 | 443.56 | 382.3 | 93.81 | Upgrade |
Long-Term Deferred Tax Liabilities | 430.8 | 426.97 | 344.12 | 447.46 | 401.07 | Upgrade |
Other Current Liabilities | 2,953 | 3,128 | 1,298 | 825.47 | 3,171 | Upgrade |
Other Long-Term Liabilities | 2,655 | 2,622 | 7,083 | 1,381 | 1,416 | Upgrade |
Total Liabilities | 70,012 | 62,598 | 52,824 | 48,308 | 47,761 | Upgrade |
Common Stock | 9,903 | 9,903 | 9,903 | 8,116 | 2,755 | Upgrade |
Retained Earnings | 11,144 | 8,326 | 6,375 | 6,360 | 6,911 | Upgrade |
Comprehensive Income & Other | 4,255 | 3,015 | 2,008 | 5,766 | 7,386 | Upgrade |
Total Common Equity | 25,303 | 21,244 | 18,287 | 20,242 | 17,051 | Upgrade |
Minority Interest | 520.79 | 461.84 | 399.17 | 330.79 | 287.14 | Upgrade |
Shareholders' Equity | 25,824 | 21,706 | 18,686 | 20,573 | 17,339 | Upgrade |
Total Liabilities & Equity | 95,835 | 84,304 | 71,510 | 68,881 | 65,100 | Upgrade |
Filing Date Shares Outstanding | 15.19 | 15.19 | 15.19 | 15.19 | 8.78 | Upgrade |
Total Common Shares Outstanding | 15.19 | 15.19 | 15.19 | 15.19 | 8.78 | Upgrade |
Total Debt | 1,349 | 1,662 | 1,202 | 459.05 | 107.47 | Upgrade |
Net Cash (Debt) | 2,034 | 1,882 | 1,291 | 1,743 | 3,063 | Upgrade |
Net Cash Growth | 8.08% | 45.84% | -25.94% | -43.12% | 21.41% | Upgrade |
Net Cash Per Share | 97.84 | 128.63 | 90.75 | 181.73 | 348.96 | Upgrade |
Book Value Per Share | 1665.86 | 1398.66 | 1203.94 | 1332.69 | 1942.44 | Upgrade |
Tangible Book Value | 25,078 | 21,096 | 18,208 | 20,144 | 17,006 | Upgrade |
Tangible Book Value Per Share | 1651.06 | 1388.89 | 1198.74 | 1326.21 | 1937.28 | Upgrade |
Land | - | - | 1,127 | 702.44 | 602.63 | Upgrade |
Buildings | - | - | 8,343 | 8,681 | 8,075 | Upgrade |
Machinery | - | - | - | 3,227 | 3,039 | Upgrade |
Construction In Progress | - | - | 320.49 | 420.13 | - | Upgrade |
Source: S&P Global Market Intelligence. Insurance template. Financial Sources.